Advertisement

Pharmacosexology: Psychiatric Side Effects of Drugs for the Treatment of Sexual Dysfunction

  • Carmita Helena Najjar Abdo
Chapter
Part of the Trends in Andrology and Sexual Medicine book series (TASM)

Abstract

Many medications are used nowadays to improve male and female sexual function. But, it is known that such drugs that are appropriate for some aspects of sexual function in turn may be deleterious leading to the development of a different kind of sexual dysfunction. Moreover, drugs adopted for comorbid psychiatric symptoms of sexual dysfunction, as antidepressant, may cause sexual side effects. Again, there are quite a number of medicines used to treat systemic conditions, as hypertension, that may impair some domains of sexual function, as erectile capability. Finally some psychotropic drugs may be used as an off-label treatment for sexual dysfunctions. In this chapter all these issues are reviewed.

References

  1. 1.
    Aversa A, Morgentaler A. The practical management of testosterone deficiency in men. Nat Rev Urol. 2015;12(11):641–50.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014;15(9):1247–64.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Hatzimouratidis K, Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, McCullough A, Torres LO, Khera M. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(4):465–88.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, Santoro N. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489–510.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med. 2007;4(2):497–501.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Gao Z, Yang D, Yu L, Cui Y. Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: a systematic review and meta-analysis. J Sex Med. 2015;12(11):2095–104.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006;26(5):482–8.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Rosen RC, Kostis JB, Jekelis AW. Beta-blocker effects on sexual function in normal males. Arch Sex Behav. 1988;17(3):241–85.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep. 2012;14(4):285–92.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    White JM, Rumbold GR. Behavioural effects of histamine and its antagonists: a review. Psychopharmacology (Berl). 1988;95(1):1–14.CrossRefGoogle Scholar
  11. 11.
    Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med. 2014;126(2):91–9.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013;202:396–7.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry. 2006;67(Suppl 6):33–7.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Bijlsma EY, Chan JS, Olivier B, Veening JG, Millan MJ, Waldinger MD, Oosting RS. Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav. 2014;121:88–101.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry. 2015;28(6):418–23.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat. 2013;2013:256841.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Ashton AK, Mahmood A, Iqbal F. Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram. J Sex Marital Ther. 2005;31(3):257–62.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    La Torre A, Giupponi G, Duffy D, Conca A. Sexual dysfunction related to psychotropic drugs: a critical review—part I: antidepressants. Pharmacopsychiatry. 2013;46(5):191–9.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67–85.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–66.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;5:CD003382.Google Scholar
  22. 22.
    Kennedy SH, Fulton KA, Bagby RM, Greene AL, Cohen NL, Rafi-Tari S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatr. 2006;51(4):234–42.CrossRefGoogle Scholar
  23. 23.
    Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28(3):329–33.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther. 1997;61(4):476–87.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008;68(5):653–89.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006;67(5):736–46.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther. 2001;23(7):1040–58.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR, Lineberry CG. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;54(12):459–65.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21(4):643–58.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155(11):772–85.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62(Suppl 3):10–21.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Gelenberg AJ, McGahuey C, Laukes C, Okayli G, Moreno F, Zentner L, Delgado P. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry. 2000;61(5):356–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Wade A, Crawford GM, Angus M, Wilson R, Hamilton L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol. 2003;18(3):133–41.PubMedGoogle Scholar
  34. 34.
    Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ, Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19(2):137–46.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Clayton AH, Gommoll C, Chen D, Nunez R, Mathews M. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial. Int Clin Psychopharmacol. 2015;30(4):216–23.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Clayton AH, Kennedy SH, Edwards JB, Gallipoli S, Reed CR. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med. 2013;10(10):2465–76.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72(4):441–7.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2012;66(4):356–68.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011;31(5):643–6.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326–33.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Clayton AH, Durgam S, Tang X, Chen C, Ruth A, Gommoll C. Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies. Neuropsychiatr Dis Treat. 2016;12:1467–76.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Jacobsen PL, Clayton AH, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. The effect of vortioxetine on sexual dysfunction in adults with major depressive disorder or generalized anxiety disorder. ASCP Meeting. Hollywood. 2014.Google Scholar
  43. 43.
    Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12(10):2036–48.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr. 2016;21(5):367–78.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry. 2013;46(6):201–8.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015;41(3):674–86.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encéphale. 2014;40(1):86–94.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Schmidt HM, Hagen M, Kriston L, Soares-Weiser K, Maayan N, Berner MM. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev. 2012;11:CD003546.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. Br J Psychiatry. 1999;175:336–9.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009;10(9):1511–26.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf. 2001;24(13):969–78.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Clayton AH, Alkis AR, Parikh NB, Votta JG. Sexual dysfunction due to psychotropic medications. Psychiatr Clin N Am. 2016;39(3):427–63.CrossRefGoogle Scholar
  54. 54.
    Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28(Suppl 2):109–23.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Haberfellner EM. A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials. Pharmacopsychiatry. 2007;40(5):173–82.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–66.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Labbate LA, Croft HA, Oleshansky MA. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. J Clin Psychiatry. 2003;64(Suppl 10):11–9.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Montejo AL, Deakin JF, Gaillard R, Harmer C, Meyniel F, Jabourian A, Gabriel C, Gruget C, Klinge C, MacFayden C, Milligan H, Mullings E, Goodwin G. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. J Psychopharmacol. 2015;29(10):1119–28.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482–91.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Barbui C, Nosè M, Bindman J, Schene A, Becker T, Mazzi MA, Kikkert M, Camara J, Born A, Tansella M. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005;25(6):521–6.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry. 2002;63(7):610–5.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Shiloh R, Weizman A, Weizer N, Dorfman-Etrog P, Munitz H. Risperidone-induced retrograde ejaculation. Am J Psychiatry. 2001;158(4):650.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Clayton AH, Baker RA, Sheehan JJ, Cain ZJ, Forbes RA, Marler SV, Marcus R, Berman RM, Thase ME. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes. 2014;7:459.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry. 2001;158(10):1623–30.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Araujo AB, Durante R, Feldman HA, Goldstein I, McKinley J. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60(4):458–65.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Seidman SN, Roose SP. The relationship between depression and erectile dysfunction. Curr Psychiatry Rep. 2000;2(3):201–5.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Seidman SN, Shabsigh R, Roose S. Pharmacologic treatments of sexual dysfunction. In: Dunner DL, editor. Psychiatric clinics of North America annual of drug therapy. Philadelphia: WB Saunders; 1999. p. 21–33.Google Scholar
  69. 69.
    Zurowski K, Kayne H, Goldstein I. The social and behavioral costs of organic impotence (Abstract). J Urol. 1994;319A:151.Google Scholar
  70. 70.
    Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L, Porto R, Bangerter K, Seger M, Montorsi F, Vardenafil Study Site Investigators. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry. 2006;163(1):79–87.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Shim YS, Pae CU, Cho KJ, Kim SW, Kim JC, Koh JS. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. Int J Impot Res. 2014;26(2):76–80.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–44.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology. 1998;52(5):848–52.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Althof SE. Quality of life and erectile dysfunction. Urology. 2002;59(6):803–10.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Cappelleri JC, Althof SE, Siegel RL, Stecher VJ, Tseng LJ, Duttagupta S. Association between the erectile dysfunction inventory of treatment satisfaction and the self-esteem and relationship questionnaire following treatment with sildenafil citrate for men with erectile dysfunction. Value Health. 2005;8(1 suppl):S54–60.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Althof SE, O’Leary MP, Cappelleri JC, Glina S, King R, Tseng LJ, Bowler JL. Self-esteem, confidence and relationships in men treated with sildenafil citrate for erectile dysfunction: results of two double-blind, placebo-controlled trials. J Gen Intern Med. 2006;21(10):1069–74.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Althof SE, O’Leary MP, Cappelleri JC, Hvidsten K, Stecher VJ, Glina S, King R, Siegel RL. Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: results from an international, multi-center, double-blind, placebo-controlled trial. J Sex Med. 2006;3(3):521–9.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Cappelleri JC, Duttagupta S, Shpilsky A, Diuguid C, Stecher V, Sweeney M, Althof S. Correlating scores on the erectile dysfunction inventory of treatment satisfaction (EDITS) with the self-esteem and relationship (SEAR) questionnaire following treatment with Viagra (sildenafil citrate) for men with erectile dysfunction: results from a multi-center open-label study. Qual Life Res. 2002;11:668.Google Scholar
  79. 79.
    O’Leary MP, Althof SE, Cappelleri JC, Crowley A, Sherman N, Duttagupta S. Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo-controlled study in the United States. J Urol. 2006;175(3 Pt 1):1058–62.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Steidle CP, Stecher VJ, Pace C, Tseng LJ. Correlation of improved erectile function and rate of successful intercourse with improved emotional wellbeing assessed with the self-esteem and relationship questionnaire in men treated with sildenafil for erectile dysfunction and stratified by age. Curr Med Res Opin. 2006;22(5):939–48.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Shim YS, Pae CU, Kim SW, Kim HW, Kim JC, Koh JS. Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study. Int J Impot Res. 2011;23(3):109–14.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Willke RJ, Glick HA, McCarron TJ, Erder MH, Althof SE, Linet OI. Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol. 1997;157(6):2124–8.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Rosen RC, Seidman SN, Menza MA, Shabsigh R, Roose SP, Tseng LJ, Orazem J, Siegel RL. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res. 2004;16(4):334–40.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Williams G, Abbou CC, Amar ET, Desvaux P, Flam TA, Ljcklama GA, Nileholt A, Lynch SF, Morgan RJ, Müller SC, Porst H, Pryor JP, Ryan P, Witzsch UK, Hall MM, Place VA, Spivack AP, Todd LK, Gesundheit N. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group. Br J Urol. 1998;82(6):847–54.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Muller MJ, Benkert O. Lower self-reported depression in patients with erectile dysfunction after treatment with sildenafil. J Affect Disord. 2001;66(2–3):255–61.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Paige NM, Hays RD, Litwin MS, Rajfer J, Shapiro MF. Improvement in emotional well-being and relationships of users of sildenafil. J Urol. 2001;166(5):1774–8.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Seidman SN, Roose RP. Sexual dysfunction and depression. Curr Psychiatry Rep. 2001;3(3):202–8.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Morgentaler A, Barada J, Niederberger C, Donatucci C, Garcia CS, Natanegara F, Ahuja S, Wong DG. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: use of a novel noninferiority study design. J Sex Med. 2006;3(3):492–503.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Nurnberg HG, Gelenberg A, Hargreave TB, Harrison W, Siegel R, Smith M. Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Am J Psychiatry. 2001;158(11):1926–8.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Tignol J, Furlan PM, Gomez-Beneyto M, Opsomer R, Schreiber W, Sweeney M, Wohlhuter C. Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. Int Clin Psychopharmacol. 2004;19(4):191–9.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Derogatis LR, Meyer JK, King KM. Psychopathology in individuals with sexual dysfunction. Am J Psychiatry. 1981;138(6):757–63.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Mallis D, Moysidis K, Nakopoulou E, Papaharitou S, Hatzimouratidis K, Hatzichristou D. Psychiatric morbidity is frequently undetected in patients with erectile dysfunction. J Urol. 2005;174(5):1913–6.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Mihalca R, Bocchio M, Pelliccione F, Ciociola F, Necozione S, Rossi A, Francavilla F, Francavilla S. Psychological features in men with erectile dysfunction with or without preclinical atherosclerosis. Int J Impot Res. 2007;19(6):597–601.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Dean J, de Boer B-J, Graziottin A, Hatzichristou D, Heaton J, Tailor A. Psychological, social, and behavioural benefits for men following effective erectile dysfunction (ED) treatment: men who enjoy better sex experience improved psychological well-being. Eur Urol. 2006;5:773–8.CrossRefGoogle Scholar
  95. 95.
    Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, Suardi N, Cestari A, Montorsi P, Rigatti P. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol. 2005;47(5):612–21.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Nurnberg HG, Siegel R. Phosphodiesterase type 5 inhibitor treatment of erectile dysfunction may impart long-term benefits for patients with depression. Presented at 30th Annual Meeting of the American Society for Andrology, Seattle. 2005.Google Scholar
  97. 97.
    Lewis RW, Sadovsky R, Eardley I, O’Leary M, Seftel A, Wang WC, Shen W, Walker DJ, Wong DG, Ahuja S. The efficacy of tadalafil in clinical populations. J Sex Med. 2005;2(4):517–31.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, Ioannidis E. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol. 2005;47(4):518–23.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Stecher VJ, Tseng L-J. Increased rate of successful intercourse correlates with improved self-esteem in men with erectile dysfunction treated with Viagra (sildenafil citrate). J Sex Med. 2005;2(Suppl 1):83. (abstract no. P–157).Google Scholar
  100. 100.
    King R, Juenemann KP, Levinson IP, Stecher VJ, Creanga DL. Correlations between increased erection hardness and improvements in emotional well-being and satisfaction outcomes in men treated with sildenafil citrate for erectile dysfunction. Int J Impot Res. 2007;19(4):398–406.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Glina S, Damião R, Abdo C, Afif-Abdo J, Tseng LJ, Stecher V. Self-esteem, confidence, and relationships in Brazilian men with erectile dysfunction receiving sildenafil citrate: a randomized, parallel-group, double-blind, placebo-controlled study in Brazil. J Sex Med. 2009;6(1):268–75.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Montorsi F, Padma-Nathan H, Glina S. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). Urology. 2006;68(3 Suppl):26–37.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Bocchio M, Pelliccione F, Mihalca R, Ciociola F, Necozione S, Rossi A, Francavilla F, Francavilla S. Treatment of erectile dysfunction reduces psychological distress. Int J Androl. 2009;32(1):74–80.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61(1):201–6.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Nicolosi A, Moreira ED Jr, Villa M, Glasser DB. A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J Affect Disord. 2004;82(2):235–43.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Cameron A, Sun P, Lage M. Comorbid conditions in men with ED before and after ED diagnosis: a retrospective database study. Int J Impot Res. 2006;18(4):375–81.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Moncada I, Martínez-Jabaloyas JM, Rodriguez-Vela L, Gutiérrez PR, Giuliano F, Koskimaki J, Farmer IS, Renedo VP, Schnetzler G. Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial. J Sex Med. 2009;6(12):3469–77.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, Adaikan PG, Becher E, Broderick GA, Buvat J, Dabees K, Giraldi A, Giuliano F, Hellstrom WJ, Incrocci L, Laan E, Meuleman E, Perelman MA, Rosen RC, Rowland DL, Segraves R. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med. 2008;5(7):1590–606.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Giuliano F, Hellstrom WJ. The pharmacological treatment of premature ejaculation. BJU Int. 2008;102(6):668–75.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    McCarty E, Dinsmore W. Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation. Core Evid. 2012;7:1–14.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Janssen-Cilag (New Zealand) Ltd. Priligy_data sheet [online]. http://www.medsafe.govt.nz/Profs/Datasheet/p/Priligytab.pdf. Accessed 20 Apr 2017.
  112. 112.
    Hoy SM, Scott LJ. Dapoxetine: in premature ejaculation. Drugs. 2010;70(11):1433–43.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Safarinejad MR. Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology. 2008;33(6):1259–65.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. 2006;46(3):301–9.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol. 1997;11(1):72–82.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    McMahon CG. Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012;4(5):233–51.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16(5):356–62.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160(4):790–2.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Tamam L, Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther. 2002;19(1):17–26.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997;58(7):291–7.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, Tesfaye F, Rothman M, Rivas DA, Porst H. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2011;8(2):524–39.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Casey R, Tesfaye F, Mudumbi R, Rothman M, Rivas D. Effects of dapoxetine for the treatment of premature ejaculation on erectile function and scales of mood and affect. Eur Urol. 2008;7(3):186.CrossRefGoogle Scholar
  123. 123.
    Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int. 2009;103(5):651–8.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol. 2005;63(4):381–94.CrossRefGoogle Scholar
  125. 125.
    Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N, The Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):839–53.Google Scholar
  126. 126.
    Allan CA, Forbes EA, Strauss BJ, McLachlan RI. Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. Int J Impot Res. 2008;20(4):396–401.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Liu PY, Swerdloff RS, Veldhuis JD. Clinical review 171: the rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab. 2004;89(10):4789–96.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Shelton JB, Rajfer J. Androgen deficiency in aging and metabolically challenged men. Urol Clin North Am. 2012;39(1):63–75.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Travison TG, Morley JE, Araujo AB, O’Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab. 2006;91(7):2509–13.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3578–83.PubMedPubMedCentralGoogle Scholar
  131. 131.
    Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl. 1992;13(4):297–304.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1999;84(2):573–7.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Rizvi SJ, Kennedy SH, Ravindran LN, Giacobbe P, Eisfeld BS, Mancini D, McIntyre RS. The relationship between testosterone and sexual function in depressed and healthy men. J Sex Med. 2010;7(2 Pt 1):816–25.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry. 2005;66(1):7–14.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Almeida OP, Yeap BB, Hankey GJ, Jamrozik K, Flicker L. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry. 2008;65(3):283–9.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Almehmadi Y, Yassin AA, Nettleship JE, Saad F. Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism. Arab J Urol. 2016;14(1):31–6.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    El-Sakka AI. Erectile dysfunction, depression, and ischemic heart disease: does the existence of one component of this triad necessitate inquiring the other two? J Sex Med. 2011;8(4):937–40. quiz 941.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Tan HM, Tong SF, Ho CC. Men’s health: sexual dysfunction, physical, and psychological health – is there a link? J Sex Med. 2012;9(3):663–71.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Pastuszak AW, Badhiwala N, Lipshultz LI, Khera M. Depression is correlated with the psychological and physical aspects of sexual dysfunction in men. Int J Impot Res. 2013;25(5):194–9.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Chung SD, Kao LT, Lin HC, Xirasagar S, Huang CC, Lee HC. Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder. PLoS One. 2017;12(3):e0173266.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Zitzmann M. Testosterone and the brain. Aging Male. 2006;9(4):195–9.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry. 2014;26(1):19–32.PubMedPubMedCentralGoogle Scholar
  143. 143.
    Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–98.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Loizides E, Swierzewski MJ, O’neill C, Griesser J, Smith T. Early response time in sexual activity and mood following testosterone gel replacement in hypogonadal males from the Testim(R) START study. Rev Urol. 2004;6(Suppl 6):S16–21.PubMedPubMedCentralGoogle Scholar
  145. 145.
    McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91(1):69–74.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Hwang TI, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res. 2006;18(4):400–4.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Morley JE, Tariq SH. Sexuality and disease. Clin Geriatr Med. 2003;19(3):563–73.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8(1):284–93.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Gades NM, Jacobson DJ, McGree ME, St Sauver JL, Lieber MM, Nehra A, Girman CJ, Klee GG, Jacobsen SJ. The associations between serum sex hormones, erectile function, and sex drive: the Olmsted County Study of urinary symptoms and health status among men. J Sex Med. 2008;5(9):2209–20.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010;7(4 Pt 2):1627–56.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Corona G, Mannucci E, Petrone L, Giommi R, Mansani R, Fei L, Forti G, Maggi M. Psycho-biological correlates of hypoactive sexual desire in patients with erectile dysfunction. Int J Impot Res. 2004;16(3):275–81.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572–82.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966–72.PubMedGoogle Scholar
  154. 154.
    Permpongkosol S, Tantirangsee N, Ratana-olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med. 2010;7(11):3765–74.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Amiaz R, Pope HG Jr, Mahne T, Kelly JF, Brennan BP, Kanayama G, Weiser M, Hudson JI, Seidman SN. Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial. J Sex Marital Ther. 2011;37(4):243–54.PubMedCrossRefGoogle Scholar
  156. 156.
    Dueñas H, Brnabic AJ, Lee A, Montejo AL, Prakash S, Casimiro-Querubin ML, Khaled M, Dossenbach M, Raskin J. Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period. Int J Psychiatry Clin Pract. 2011;15(4):242–54.PubMedCrossRefGoogle Scholar
  157. 157.
    Derogatis LR. Sexual function and quality of life: endpoints and outcomes. J Gend Specif Med. 2001;4(4):35–42.PubMedPubMedCentralGoogle Scholar
  158. 158.
    Rothschild AJ. New directions in the treatment of antidepressant-induced sexual dysfunction. Clin Ther. 2000;22:A42–57. discussion A8–61.PubMedCrossRefGoogle Scholar
  159. 159.
    Clayton A. The impact of antidepressant associated sexual dysfunction on treatment adherence in patients with major depressive disorder. Curr Psychiatr Rev. 2013;9(4):293–301.CrossRefGoogle Scholar
  160. 160.
    Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009;29(2):157–64.CrossRefPubMedPubMedCentralGoogle Scholar
  161. 161.
    Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000;61(Suppl 2):20–5.PubMedGoogle Scholar
  162. 162.
    Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousoño M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176–94.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159–66.PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Segraves RT, Croft H, Kavoussi R, Ascher JA, Batey SR, Foster VJ, Bolden-Watson C, Metz A. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in non-depressed women. J Sex Marital Ther. 2001;27(3):303–16.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Segraves RT, Clayton A, Croft H, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol. 2004;24(3):339–42.PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    IsHak WW, Davis M, Jeffrey J, Balayan K, Pechnick RN, Bagot K, Rapaport MH. The role of dopaminergic agents in improving quality of life in major depressive disorder. Curr Psychiatry Rep. 2009;11(6):503–8.PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    Demyttenaere K, Jaspers L. Review: bupropion and SSRI-induced side effects. J Psychopharmacol. 2008;22(7):792–804.PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA. 15 years of clinical experience to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106–13.PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    Fortner MR, Brown K, Varia IM, Gersing KR, O’Connor C, Doraiswamy PM. Effect of bupropion SR on the quality of life of elderly depressed patients with comorbid medical disorders. Prim Care Companion J Clin Psychiatry. 1999;1(6):174–9.PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Dunner DL, Kwong WJ, Houser TL, Richard NE, Donahue RM, Khan ZM. Improved health-related quality of life and reduced productivity loss after treatment with bupropion sustained release: a study in patients with major depression. Prim Care Companion J Clin Psychiatry. 2001;3(1):10–6.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Herrera-Guzman I, Gudayol-Ferre E, Lira-Mandujano J, Herrera-Abarca J, Herrera-Guzmán D, Montoya-Pérez K, Guardia-Olmos J. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res. 2008;160(1):72–82.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(6):865–73.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf. 2014;13(10):1361–74.PubMedCrossRefPubMedCentralGoogle Scholar
  174. 174.
    Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004;65(1):62–7.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Segraves RT, Balon R. Antidepressant-induced sexual dysfunction in men. Pharmacol Biochem Behav. 2014;121:132–7.PubMedCrossRefPubMedCentralGoogle Scholar
  176. 176.
    Segraves RT, Kavoussi R, Hughes AR, Batey SR, Johnson JA, Donahue R, Ascher JA. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol. 2000;20(2):122–8.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016;6(2):99–144.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    Bupropion [prescribing information]. Research Triangle Park: GlaxoSmithKline. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Wellbutrin_Tablets/pdf/wellbutrin-tablets-pi-mg.pdf. Revised April 2016. Accessed 21 Apr 2017.
  179. 179.
    Yang BK, Donatucci CF. Drugs that affect male sexual function. In: Mulcahy J, editor. Male sexual function: a guide to clinical management. 2nd ed. Totowa: Humana; 2006. p. 155–94.CrossRefGoogle Scholar
  180. 180.
    Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8(1):15–27.PubMedCrossRefPubMedCentralGoogle Scholar
  181. 181.
    Presentation at meeting of the FDA advisory committee for reproductive health drugs. 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm248751.pdf. Published June 18, 2010. Accessed 8 May 2017.
  182. 182.
    Popova NK, Amstislavskaya TG. Involvement of the 5-HT (1A) and 5-HT (1B) serotonergic receptor subtypes in sexual arousal in male mice. Psychoneuroendocrinology. 2002;27(5):609–18.PubMedCrossRefPubMedCentralGoogle Scholar
  183. 183.
    Sang JH, Kim TH, Kim SA. Flibanserin for treating hypoactive sexual desire disorder. J Menopausal Med. 2016;22(1):9–13.PubMedPubMedCentralCrossRefGoogle Scholar
  184. 184.
    Kennedy S. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med. 2010;7(10):3449–59.PubMedCrossRefPubMedCentralGoogle Scholar
  185. 185.
    Flibanserin [prescribing information]. Bridgewater: Valeant Pharmaceuticals. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf. Accessed 2 May 2017.
  186. 186.
    Katz M, Derogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, Sand M, BEGONIA trial investigators. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807–15.PubMedCrossRefPubMedCentralGoogle Scholar
  187. 187.
    Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633–40.PubMedCrossRefPubMedCentralGoogle Scholar
  188. 188.
    Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women: Flibanserin Advisory Committee briefing document. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetyandriskmanagementadvisorycommittee/ucm449090.pdf. Published June 4, 2015. Accessed 15 Apr 2017.
  189. 189.
    US Food and Drug. FDA briefing document. US food and drug. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm458734.htm. Published August 18, 2015. Accessed 15 Apr 2017.
  190. 190.
    Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114–28.PubMedCrossRefPubMedCentralGoogle Scholar
  191. 191.
    Brotto LA. Evidence-based treatments for low sexual desire in women. Front Neuroendocrinol. 2017;45:11–7.PubMedCrossRefPubMedCentralGoogle Scholar
  192. 192.
    Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–62.PubMedCrossRefPubMedCentralGoogle Scholar
  193. 193.
    Sahebkar A, Saadat SH, Panahi Y, Kabir A, Rahmani K, Hosseinialhashemi M. Systematic review and meta-analysis of flibanserin’s effects and adverse events in women with hypoactive sexual desire disorder. Curr Drug Metab. 2016. Online publication. http://benthamscience.com/journals/currentdrug-metabolism/. Accessed 26 May 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department and Institute of Psychiatry, Program of Studies in Sexuality (ProSex), Medical SchoolUniversity of Sao Paulo (FMUSP)Sao PauloBrazil

Personalised recommendations